Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China
· Delayed Price · Currency is CNY 37.08
+2.98 (8.74%)
Mar 11, 2026, 9:25 AM CST
SHE:300683 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -187.7 | -69.35 | -120.82 | -14.03 | 27.65 | -25.03 | Upgrade
|
| Depreciation & Amortization | 91.14 | 91.14 | 71.07 | 53.47 | 37.91 | 28.99 | Upgrade
|
| Other Amortization | 5.24 | 5.24 | 1.66 | 0.78 | 0.8 | 0.95 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.07 | 0.07 | 0.36 | 0.09 | 0.18 | 0.09 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.15 | 1.15 | 42.59 | 17.22 | 0.02 | 14.61 | Upgrade
|
| Loss (Gain) From Sale of Investments | -6.48 | -6.48 | -17.58 | -23.72 | -14.01 | 0.63 | Upgrade
|
| Provision & Write-off of Bad Debts | 9.46 | 9.46 | -4.24 | 15.85 | 13.38 | 11.8 | Upgrade
|
| Other Operating Activities | 22.33 | 7.76 | 20.07 | 11.24 | 2.93 | 12.87 | Upgrade
|
| Change in Accounts Receivable | -51.76 | -51.76 | 24.42 | 13.49 | -67.5 | -16.41 | Upgrade
|
| Change in Inventory | -1.53 | -1.53 | -21.9 | -52.45 | -0.75 | -1.81 | Upgrade
|
| Change in Accounts Payable | 49.21 | 49.21 | 35.19 | 34.18 | 26.17 | -22.78 | Upgrade
|
| Operating Cash Flow | -81.1 | 22.69 | 5.31 | 53.03 | 12.09 | -19.7 | Upgrade
|
| Operating Cash Flow Growth | - | 326.89% | -89.98% | 338.72% | - | - | Upgrade
|
| Capital Expenditures | -61.2 | -43.08 | -167.44 | -173.97 | -247.11 | -113.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.48 | 0.02 | 2.07 | 0.02 | 0.02 | 0.04 | Upgrade
|
| Cash Acquisitions | - | - | - | -22.72 | -197 | -22.68 | Upgrade
|
| Divestitures | - | - | - | 3 | 4.28 | 0.54 | Upgrade
|
| Investment in Securities | -126.99 | -70.09 | -345.86 | 704.01 | -528.15 | -81.91 | Upgrade
|
| Other Investing Activities | -36.81 | 12.8 | 19.3 | 15.02 | 14.96 | 21.51 | Upgrade
|
| Investing Cash Flow | -224.52 | -100.35 | -491.93 | 525.36 | -953.01 | -196.14 | Upgrade
|
| Long-Term Debt Issued | - | - | 10 | - | 84.97 | 40 | Upgrade
|
| Long-Term Debt Repaid | - | -18.52 | -49.09 | -8.06 | -8.34 | -39 | Upgrade
|
| Net Debt Issued (Repaid) | -11.64 | -18.52 | -39.09 | -8.06 | 76.63 | 1 | Upgrade
|
| Issuance of Common Stock | 4 | - | 290 | - | 589.97 | - | Upgrade
|
| Common Dividends Paid | -18.06 | -1.76 | -2.2 | -1.34 | -0.06 | -16.98 | Upgrade
|
| Other Financing Activities | 5.8 | 6.85 | -0.42 | -2.89 | -3.72 | 7.8 | Upgrade
|
| Financing Cash Flow | -19.9 | -13.43 | 248.29 | -12.29 | 662.82 | -8.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.05 | 0.04 | 0.01 | 0.05 | -0.04 | -0.08 | Upgrade
|
| Net Cash Flow | -325.47 | -91.04 | -238.31 | 566.15 | -278.15 | -224.1 | Upgrade
|
| Free Cash Flow | -142.29 | -20.39 | -162.13 | -120.94 | -235.02 | -133.33 | Upgrade
|
| Free Cash Flow Margin | -22.96% | -3.14% | -26.92% | -17.56% | -38.23% | -25.44% | Upgrade
|
| Free Cash Flow Per Share | -1.10 | -0.16 | -1.25 | -0.95 | -2.21 | -1.28 | Upgrade
|
| Cash Interest Paid | 0 | 0 | 0 | 0.31 | - | - | Upgrade
|
| Cash Income Tax Paid | 31.09 | 27.88 | -9.15 | 9.34 | 20.24 | 24.92 | Upgrade
|
| Levered Free Cash Flow | -101.63 | -37.93 | -100.86 | -122.1 | -430.98 | -165.96 | Upgrade
|
| Unlevered Free Cash Flow | -100.81 | -36.49 | -99.36 | -121.4 | -430.67 | -165.67 | Upgrade
|
| Change in Working Capital | -16.29 | -16.29 | 12.2 | -7.88 | -56.78 | -64.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.